Egyptian Foundation for Cancer Research Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2004
NCT00085163
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

EFCR - Egyptian foundation for Cancer Research | Egyptian Foundation For Cancer Research

Active Ingredients

Drugs in Phase 3 Trials (3)

celecoxib (celebrex) (1 trial)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

Drugs in Phase 2 Trials (1)

sorafenib (nexavar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4